Co-administration of raltegravir reduces daily darunavir exposure in HIV-1 infected patients

Pharmacological Research

Volumn 65, Issue 2, 2012, Pages 198-203

  Cattaneo, Dario ^a   Gervasoni, Cristina ^a   Cozzi, Valeria ^a   Baldelli, Sara ^a   Fucile, Serena ^a   Meraviglia, Paola ^a   Landonio, Simona ^a   Boreggio, Gabriella ^a   Rizzardini, Giuliano ^a   Clementi, Emilio ^a,b  

^a UNIVERSITY OF MILAN   (Italy)

^b SCIENTIFIC INSTITUTE   (Italy)

Author keywords

Darunavir; Drug to drug interactions; HIV; Pharmacokinetics; Raltegravir; Ritonavir

Indexed keywords

DARUNAVIR; RALTEGRAVIR; RITONAVIR;

ADULT; AREA UNDER THE CURVE; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG ELIMINATION; DRUG POTENTIATION; DRUG UPTAKE; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MORNING DOSAGE; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL;

ADULT; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MALE; MIDDLE AGED; PYRROLIDINONES; RITONAVIR; SULFONAMIDES;

EID: 84856018356     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2011.09.006     Document Type: Article

References (25)

1. P.A. Volberding, and S.G. Deeks Antiretroviral therapy and management of HIV infection Lancet 376 2010 49 56
2. A. Lafeuillade Potential strategies for an HIV infection cure HIV Clin Trials 12 2011 121 130
3. B. Taiwo, R.L. Murphy, and C. Katlama Novel antiretroviral combinations in treatment-experienced patients with HIV infection: rationale and results Drugs 70 2010 1629 1642
4. K. McKeage, C.M. Perry, and S.J. Keam Darunavir: a review of its use in the management of HIV infection in adults Drugs 69 2009 477 503
5. M. Boffito, D. Miralles, and A. Hill Pharmacokinetics, efficacy, and safety of darunavir/ritonavir 800/100 mg once-daily in treatment-naïve and -experienced patients HIV Clin Trials 9 2008 418 427
6. C. Fenton, and C.M. Perry Darunavir in the treatment of HIV-1 infection Drugs 67 2007 2791 2801
7. D.M. Brainard, L.A. Wenning, J.A. Stone, J.A. Wagner, and M. Iwamoto Clinical pharmacology profile of raltegravir, an HIV-1 integrase strand transfer inhibitor J Clin Pharmacol 2011 [Epub ahead of print]
8. W. Towner, J. Lalezari, M.G. Sension, M. Wohlfeiler, J. Gathe, and J.S. Appelbaum Efficacy, safety, and tolerability of etravirine with and without darunavir/ritonavir or raltegravir in treatment-experienced patients: analysis of the etravirine early access program in the United States J Acquir Immune Defic Syndr 53 2010 614 618
9. Y. Yazdanpanah, C. Fagard, D. Descamps, A.M. Taburet, C. Colin, and B. Roquebert High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial Clin Infect Dis 49 2009 1441 1449
10. T. Antoniou, J.M. Raboud, C. Diong, D. Su, N. Dewhurst, and V. Buckley Virologic and immunologic effectiveness of tipranavir/ritonavir (TPV/r)- versus darunavir/ritonavir (DRV/r)-based regimens in clinical practice J Int Assoc Physicians AIDS Care (Chic) 9 2010 382 389
11. L. Dickinson, S. Khoo, and D. Back Pharmacokinetics and drug-drug interactions of antiretrovirals: an update Antiviral Res 85 2010 176 189
12. M. Fabbiani, S. Di Giambenedetto, E. Ragazzoni, G. D'Ettorre, G. Parruti, and M. Prosperi Darunavir/ritonavir and raltegravir coadministered in routine clinical practice: potential role for an unexpected drug interaction Pharmacol Res 63 2011 249 253
13. L. Garvey, N. Latch, O.W. Erlwein, N.E. Mackie, J. Walsh, and G. Scullard The effects of a nucleoside-sparing antiretroviral regimen on the pharmacokinetics of ritonavir-boosted darunavir in HIV type-1-infected patients Antivir Ther 15 2 2010 213 218
14. L. Goldwirt, J. Braun, N. de Castro, I. Charreau, A. Barrail-Tran, and C. Delaugerre Switch from enfuvirtide to raltegravir lowers plasma concentrations of darunavir and tipranavir: a pharmacokinetic substudy of the EASIER-ANRS 138 Trial Antimicrob Agents Chemother 55 2011 3613 3615
15. D. Cattaneo, D. Ripamonti, C. Gervasoni, S. Landonio, P. Meraviglia, and S. Baldelli Limited sampling strategies for the estimation of raltegravir daily exposure in HIV-infected patients J Clin Pharmacol 2011 [Epub ahead of print]
16. A. Fayet, A. Béguin, B. Zanolari, S. Cruchon, N. Guignard, and A. Telenti A LC-tandem MS assay for the simultaneous measurement of new antiretroviral agents: raltegravir, maraviroc, darunavir, and etravirine J Chromatogr B Analyt Technol Biomed Life Sci 877 2007 1057 1069
17. FDA guidance for industry - bioanalytical method validation May 2001 Center for Drug Evaluation and Research, US Department for Health and Human Services
18. S.K. König, M. Herzog, D. Theile, N. Zembruski, W.E. Haefeli, and J. Weiss Impact of drug transporters on cellular resistance towards saquinavir and darunavir J Antimicrob Chemother 65 2010 2319 2328
19. W.S. Kwan, O. Janneh, R. Hartkoorn, B. Chandler, S. Khoo, and D. Back Intracellular 'boosting' of darunavir using known transport inhibitors in primary PBMC Br J Clin Pharmacol 68 2009 375 380
20. H. Fujimoto, M. Higuchi, H. Watanabe, Y. Koh, A.K. Ghosh, and H. Mitsuya P-glycoprotein mediates efflux transport of darunavir in human intestinal Caco-2 and ABCB1 gene-transfected renal LLC-PK1 cell lines Biol Pharm Bull 32 2009 1588 1593
21. N.C. Zembruski, G. Büchel, L. Jödicke, M. Herzog, W.E. Haefeli, and J. Weiss Potential of novel antiretrovirals to modulate expression and function of drug transporters in vitro J Antimicrob Chemother 66 2011 802 812
22. M. Cianfriglia, M.L. Dupuis, A. Molinari, A. Verdoliva, R. Costi, and C.M. Galluzzo HIV-1 integrase inhibitors are substrates for the multidrug transporter MDR1-P-glycoprotein Retrovirology 4 2007 17
23. V. Sekar, E. De Paepe, B. Van Baelen, P. Vis, F. Tomaka, and M. De Pauw Pharmacokinetic/pharmacodynamic (PK/PD) analyses of darunavir in the TITAN study 11th European AIDS conference Madrid, Spain, October 24-27 2007
24. B. Taiwo, L. Zheng, S. Gallien, R.M. Matining, D.R. Kuritzkes, and C.C. Wilson Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naïve HIV-1-infected patients (ACTG A5262) AIDS 2011 [Epub ahead of print]
25. D. Gonzalez de Requena, S. Bonora, O. Vigan, A. Calcagno, C. Cometto, and A. D'Avolio Comparative evaluation of seven resistance interpretation algorithms and their derived genotypic inhibitory quotients for the prediction of 48 week virological response to darunavir-based salvage regimens J Antimicrob Chemother 66 2011 192 200